

R/Pharma 2021

Industrialized Machine Learning and Explainable AI for Late Phase Trials

Biomarker & Data Insights
Data Science & Analytics

Karl Köchert

Adam Skubala
Antigoni Elefsinioti
Eliana Garcia Cossio
Frauke Hennig
Lidia Sacchetto
Lukas Lasota
Maike Ahrens
Sebastian Voss
Yuan Hong

bayer/bmdi

bayer/bmdi bayer/bmdi bayer/bmdi chrestos/bsds bayer/cseu clinstat chrestos/bsds chrestos/bsds bayer/bmdi



BMDI MLAI pipeline





Why do we need the MLAI pipeline?




What is the MLAI pipeline?



How does it work? How was the pipeline built?

Today's aim:

Briefly touch the Why, What and the Hows.







Why do we need the MLAI pipeline?

Motivation and added value of MLAI in late phase interventional trials

Classical approaches are "forcing" a hypothesis on the data and are limited to detection of strong, low-complexity signals using only a small amount of the variables (measured data) at one time.

By deriving the best hypothesis given the data, Machine Learning (ML) is currently the best available methodology to create holistic mathematical models of complex (biological) systems using all available data and variables.

In that sense, ML complements classical approaches to ensure prudent and as thorough as technically possible insights generation.

Explainable Al needed – focus on understanding data-outcome relations, not prediction!





Why do we need the MLAI pipeline?

Motivation and added value of using a MLAI pipeline

Standardized

to enable transparency as well as efficiency and the reusability across many projects.

Reproducible

at every step to guarantee consistency, robustness and trust.

Validated

to follow the general principles of software validation (EMA / FDA).







We provide a standardized, reproducible and validated MLAI pipeline to efficiently compute and report holistic MLAI models for clinical endpoints (classification, regression, time-to-event) based on all measured data in a clinical trial.

The pipeline's purpose is to detect clinically relevant, highly complex safety / efficacy signals that are not identifiable with classical approaches.

Find answers to questions such as

- How good is the measured data at explaining a clinical outcome / an endpoint of interest?
- What are potential drivers / features for the occurrence of an outcome?
- Do we find baseline characteristics that interact with treatment regarding the effect on the outcome?
- Can we identify potential directionality / relationship between feature values and the outcome?

The pipeline is already being used in various Bayer studies, MLAI topline close to study topline results!





General overview

A bunch of **R functions & Rmd templates**, summarized into **R packages**, summarized into the **meta package** bmdiMARTINI

- path to folder with clinical data
- prepared outcome



data preparation



model fitting and tuning



- Rmd HTML reports
- data for Shiny apps

Flexible modules

to address questions regarding the association between an outcome of interest and the collected data.

Expandable modules

for future needs.

Validated modules


so that it can be used in the clinical setting.





Module concepts


- path to folder with clinical data
- prepared outcome



model fitting and tuning

reporting

- Rmd HTML reports
- data for Shiny apps



- path_to_ads %>%
 ads_spec() %>%
 build() %>%
- 4 prepare_ml()



Module concepts


- path to folder with clinical data
- prepared outcome

data preparation

model fitting and tuning



- Rmd HTML reports
- data for Shiny apps





Module concepts


- path to folder with clinical data
- prepared outcome

data preparation

model fitting and tuning

reporting

- Rmd HTML reports
- data for Shiny apps









Thank you!

R/Pharma 2021



Provide a stable environment bmdiMARTINI
Machine learning &
ARTificial INtelligence

Summarize modules in meta package

Build one R package per module

Modularize

Unit tests

Good programming practice

Extensive documentation

